Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sperogenix Acquires China Rights to Rare Disease Candidate in $78 Million Deal

publication date: Sep 25, 2020

Sperogenix Therapeutics of Beijing in-licensed a CNS drug from Barcelona's Minoryx Therapeutics in a $78 million agreement. Sperogenix will own China rights to leriglitazone, a brain penetrating disease-modifying PPAR-y agonist. The candidate is a proposed treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening disease. Sperogenix was formed in 2019 with backing from Lilly Asia Ventures and Morningside Venture Capital to bring later clinical stage and commercial stage treatments for rare diseases to China. More details...

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital